Rosiglitazone inhibits hepatic insulin resistance induced by chronic pancreatitis and IKK-β/NF-κB expression in liver

Pancreas

Volumn 43, Issue 8, 2014, Pages 1291-1298

  Zhou, Xiaolei ^a   You, Shengyi ^a  

^a TIANJIN MEDICAL UNIVERSITY   (China)

Author keywords

Chronic pancreatitis; Hepatic insulin resistance; I kinase ; Nuclear factor B; Rosiglitazone

Indexed keywords

2 CHLORO 5 NITROBENZANILIDE; GLUCOSE; I KAPPA B KINASE BETA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INSULIN; INSULIN RECEPTOR SUBSTRATE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; ROSIGLITAZONE; SER307P INSULIN RECEPTOR SUBSTRATES 1; TRANSCRIPTION FACTOR RELA; UNCLASSIFIED DRUG; 2,4 THIAZOLIDINEDIONE DERIVATIVE; 2-CHLORO-5-NITROBENZANILIDE; ANILIDE; I KAPPA B KINASE; IRS1 PROTEIN, RAT; RELA PROTEIN, RAT;

ANIMAL EXPERIMENT; ANIMAL MODEL; AREA UNDER THE CURVE; ARTICLE; CELL ISOLATION; CHRONIC PANCREATITIS; CONTROLLED STUDY; GLUCOSE BLOOD LEVEL; GLUCOSE TOLERANCE TEST; HEPATIC INSULIN RESISTANCE; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; INSULIN SENSITIVITY; INSULIN TOLERANCE TEST; LIVER; LIVER CELL; LIVER DISEASE; MALE; NONHUMAN; PROTEIN EXPRESSION; RAT; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; WESTERN BLOTTING; AGONISTS; ANIMAL; BIOSYNTHESIS; BLOOD; DIAGNOSTIC USE; DRUG EFFECTS; DRUG SCREENING; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; PANCREATITIS, CHRONIC; SECRETION (PROCESS); WISTAR RAT;

ANILIDES; ANIMALS; DRUG EVALUATION, PRECLINICAL; GENE EXPRESSION REGULATION; GLUCOSE; GLUCOSE TOLERANCE TEST; HEPATOCYTES; I-KAPPA B KINASE; INSULIN; INSULIN RECEPTOR SUBSTRATE PROTEINS; INSULIN RESISTANCE; LIVER; MALE; PANCREATITIS, CHRONIC; PPAR GAMMA; RATS; RATS, WISTAR; THIAZOLIDINEDIONES; TRANSCRIPTION FACTOR RELA;

EID: 84916634285     PISSN: 08853177     EISSN: 15364828     Source Type: Journal    
DOI: 10.1097/MPA.0000000000000173     Document Type: Article

References (42)

1. Pezzilli R, Morselli-Labate AM. Alcoholic pancreatitis: pathogenesis, incidence and treatment with special reference to the associated pain. Int J Environ Res Public Health. 2009; 6:2763-2782.
2. Sri Manjari K, Nallari P, Vidyasagar A., et al. Plasma TGF-β1, MMP-1 and MMP-3 levels in chronic pancreatitis. Indian J Clin Biochem. 2012; 27: 152-156.
3. Niebisz-Cies̈lak AB, Karnafel W. Insulin sensitivity in chronic pancreatitis and features of insulin resistance syndrome. Pol Arch Med Wewn. 2010; 120:255-263.
4. Escribano O, Guillén C, Nevado C., et al. Beta-Cell hyperplasia induced by hepatic insulin resistance: role of a liver-pancreatic endocrine axis through insulin receptor A isoform. Diabetes. 2009; 58:820-828.
5. Fisher SJ, Kahn CR. Insulin signaling is required for insulin's direct and indirect action on hepatic glucose production. J Clin Invest. 2003; 111: 463-468.
6. Angelopoulos N, Dervenis C, Goula A., et al. Endocrine pancreatic insufficiency in chronic pancreatitis. Pancreatology. 2005; 5:122-131.
7. Seymour NE, Volpert AR, Lee E.L., et al. Alterations in hepatocyte insulin binding in chronic pancreatitis: effects of pancreatic polypeptide. Am J Surg. 1995; 169:105-109.
8. Seymour NE, Volpert AR, Andersen DK. Regulation of hepatic insulin receptors by pancreatic polypeptide in fasting and feeding. J Surg Res. 1996; 65:1-4.
9. Gao Z, Yin J, Zhang J., et al. Inactivation of NF-kappaB p50 leads to insulin sensitization in liver through post-translational inhibition of p70S6K. J Biol Chem. 2009; 284:18368-18376.
10. Wullaert A, van Loo G, Heyninck K, et al. Hepatic tumor necrosis factor signaling and nuclear factor-kappaB: effects on liver homeostasis and beyond. Endocr Rev. 2007; 28:365-386.
11. Yuan M, Konstantopoulos N, Lee J., et al. Reversal of obesity- and diet-induced insulin resistance with salicylates or targeted disruption of Ikkbeta. Science. 2001; 293:1673-1677.
12. Boyer L, Travaglione S, Falzano L., et al. Rac GTPase instructs nuclear factor-kappaB activation by conveying the SCF complex and IkBalpha to the ruffling membranes. Mol Biol Cell. 2004; 15:1124-1133.
13. Strack P, Caligiuri M, Pelletier M., et al. SCF(beta-TRCP) and phosphorylation dependent ubiquitination of I kappa B alpha catalyzed by Ubc3 and Ubc4. Oncogene. 2000; 19:3529-3536.
14. Miao H, Zhang Y, Lu Z., et al. FOXO1 involvement in insulin resistance-related pro-inflammatory cytokine production in hepatocytes. Inflamm Res. 2012; 61:349-358.
15. He B, Zhao S, Zhang W., et al. Effect of sodium salicylate on oxidative stress and insulin resistance induced by free fatty acids. Hepatobiliary Pancreat Dis Int. 2010; 9:49-53.
16. Imaeda K, Nojiri S. Hepato-biliary and pancreatic disease and osteodystrophy. Clin Calcium. 2009; 19:1275-1280.
17. Kim JK, Fillmore JJ, Gavrilova O, et al. Differential effects of rosiglitazone on skeletal muscle and liver insulin resistance in A-ZIP/F-1 fatless mice. Diabetes. 2003; 52:1311-1318.
18. DeFronzo RA, Triplitt C, Qu Y., et al. Effects of exenatide plus rosiglitazone on beta-cell function and insulin sensitivity in subjects with type 2 diabetes on metformin. Diabetes Care. 2010; 33:951-957.
19. Bai YP, Liu YH, Chen J, et al. Rosiglitazone attenuates NF-kappaB-dependent ICAM-1 and TNF-alpha production caused by homocysteine via inhibiting ERK1/2/p38MAPK activation. Biochem Biophys Res Commun. 2007; 360:20-26.
20. Remels AH, Langen RC, Gosker H.R., et al. PPARgamma inhibits NF-kappaB-dependent transcriptional activation in skeletal muscle. Am J Physiol Endocrinol Metab. 2009; 297:E174-E183.
21. Wang HN, Wang YR, Liu G.Q., et al. Inhibition of hepatic interleukin-18 production by rosiglitazone in a rat model of nonalcoholic fatty liver disease. World J Gastroenterol. 2008; 14:7240-7246.
22. Kang SB, Kim HM, Kim H.J., et al. Rosiglitazone attenuates casein-induced hepatic endoplasmic reticulum stress in Sprague-Dawley rats: a novel model of endoplasmic reticulum stress. Endocr J. 2013; 60:1231-1240.
23. Pickavance LC, Tadayyon M, Widdowson P.S., et al. Therapeutic index for rosiglitazone in dietary obese rats: separation of efficacy and haemodilution. Br J Pharmacol. 1999; 128:1570-1576.
24. Li Z, Zhu XY, Li M, et al. Protective effect of ghrelin on left ventricular remodeling in spontaneously hypertensive rats is associated with the peroxisome proliferator-activated receptor gamma-dependent pathway. Chin Med J (Engl). 2008; 121:2299-2304.
25. Rachoń D, Vortherms T, Seidlová-Wuttke D, et al. Effects of black cohosh extract on body weight gain, intra-abdominal fat accumulation, plasma lipids and glucose tolerance in ovariectomized Sprague-Dawley rats. Maturitas. 2008; 60:209-215.
26. Carvalho-Filho MA, Ropelle ER, Pauli R.J., et al. Aspirin attenuates insulin resistance in muscle of diet-induced obese rats by inhibiting inducible nitric oxide synthase production and S-nitrosylation of IRbeta/IRS-1 and Akt. Diabetologia. 2009; 52:2425-2434.
27. Eisenberg ML, Maker AV, Slezak L.A., et al. Insulin receptor (IR) and glucose transporter 2 (GLUT2) proteins form a complex on the rat hepatocyte membrane. Cell Physiol Biochem. 2005; 15:51-58.
28. Cui Y, Andersen DK. Pancreatogenic diabetes: special considerations for management. Pancreatology. 2011; 11:279-294.
29. Kuda O, Stankova B, Tvrzicka E., et al. Prominent role of liver in elevated plasma palmitoleate levels in response to rosiglitazone in mice fed high-fat diet. J Physiol Pharmacol. 2009; 60:135-140.
30. He W, Barak Y, Hevener A., et al. Adipose-specific peroxisome proliferator-activated receptor gamma knockout causes insulin resistance in fat and liver but not in muscle. Proc Natl Acad Sci USA. 2003; 100: 15712-15717.
31. Tiikkainen M, Häkkinen AM, Korsheninnikova E., et al. Effects of rosiglitazone and metformin on liver fat content, hepatic insulin resistance, insulin clearance, and gene expression in adipose tissue in patients with type 2 diabetes. Diabetes. 2004; 53:2169-2176.
32. D'Alessandris C., Lauro R, Presta I., et al. C-reactive protein induces phosphorylation of insulin receptor substrate-1 on Ser307 and Ser 612 in L6 myocytes, thereby impairing the insulin signalling pathway that promotes glucose transport. Diabetologia. 2007; 50:840-849.
33. Leesnitzer LM, Parks DJ, Bledsoe R.K., et al. Functional consequences of cysteine modification in the ligand binding sites of peroxisome proliferator-activated receptors by GW9662. Biochemistry. 2002; 41: 6640-6650.
34. Maeda N, Takahashi M, Funahashi T., et al. PPARgamma ligands increase expression and plasma concentrations of adiponectin, an adipose-derived protein. Diabetes. 2001; 50:2094-2099.
35. Park E, Wong V, Guan X., et al. Salicylate prevents hepatic insulin resistance caused by short-term elevation of free fatty acids in vivo. J Endocrinol. 2007; 195:323-331.
36. Cai D, Yuan M, Frantz D.F., et al. Local and systemic insulin resistance resulting from hepatic activation of IKK-beta and NF-kappaB. Nat Med. 2005; 11:183-190.
37. Kiechl S, Wittmann J, Giaccari A., et al. Blockade of receptor activator of nuclear factor-κB (RANKL) signaling improves hepatic insulin resistance and prevents development of diabetes mellitus. Nat Med. 2013; 19:358-363.
38. Yaspelkis BB 3rd, Kvasha IA, Figueroa TY. High-fat feeding increases insulin receptor and IRS-1 coimmunoprecipitation with SOCS-3, IKKalpha/beta phosphorylation and decreases PI-3 kinase activity in muscle. Am J Physiol Regul Integr Comp Physiol. 2009; 296:R1709-R1715.
39. Mohanty P, Aljada A, Ghanim H., et al. Evidence for a potent antiinflammatory effect of rosiglitazone. Clin Endocrinol Metab. 2004; 89: 2728-2735.
40. Dworzanski T, Celinski K, Korolczuk A., et al. Influence of the peroxisome proliferator-activated receptor gamma (PPAR-γ) agonist, rosiglitazone and antagonist, biphenol-A-diglicydyl ether (BADGE) on the course of inflammation in the experimental model of colitis in rats. J Physiol Pharmacol. 2010; 61:683-693.
41. Williams CR, Lu X, Sutliff R.L., et al. Rosiglitazone attenuates NF-γB-mediated Nox4 upregulation in hyperglycemia-activated endothelial cells. Am J Physiol Cell Physiol. 2012; 303:C213-C223.
42. Neri T, Armani C, Pegoli A., et al. Role of NF-kappaB and PPAR-gamma in lung inflammation induced by monocyte-derived microparticles. Eur Respir J. 2011; 37:1494-1502.